Fulcrum Therapeutics Inc (FULC)

$11.00 -0.73 (-6.22%)
Market Cap 634.80M
Revenue (ttm) 80.00M
Net Income (ttm) -9.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -12.16%
Debt to Equity Ratio 0.00
Volume 833,700
Avg Vol 968,660
Day's Range N/A - N/A
Shares Out 54.12M
Stochastic %K 61%
Beta 3.19
Analysts Strong Sell
Price Target $19.10

Company Profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 651 8851
Address:
26 Landsdowne Street, Cambridge, United States
elmono
elmono Feb. 20 at 7:35 PM
$FULC which retail retards are taking a few dimes profit? ….Tell me 😂😂😂
0 · Reply
HeraklesTrading
HeraklesTrading Feb. 20 at 9:10 AM
$FULC 20 mg, 12 weeks baby !! clear signs of dose response AND almost clear signs of time response !! That's why I'd expect fantastic full 12 weeks results on Tuesday ;) buckle up, above above $20 next week ;)
0 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Feb. 19 at 8:21 PM
$FULC new fda guideline means if fulc has same data at 12week as 6 week, they might try to file priority review, breakthrough, skip P3.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 2:59 PM
$FULC Current Stock Price: $11.31 Contracts to trade: $11.0 FULC Feb 20 2026 Call Entry: $0.52 Exit: $0.67 ROI: 29% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Feb. 18 at 5:50 PM
$FULC totally normal. Gsk bought 1.8m shares in fulc right? And all the top hedge funds entered. I'm waiting for the party or the funeral next Tuesday.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 11:11 PM
$FULC RSI: 51.44, MACD: -0.0898 Vol: 0.42, MA20: 10.50, MA50: 10.99 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OceanDeepValue
OceanDeepValue Feb. 4 at 3:45 PM
$FULC is a clinical-stage biotech (Fulcrum Therapeutics) developing therapies for genetically defined diseases; its pipeline is in mid-stage trials, representing a binary investment.
0 · Reply
elmono
elmono Feb. 2 at 8:48 PM
$FULC fuck fulc
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 29 at 1:10 AM
$FULC Current Stock Price: $10.49 Contracts to trade: $10 FULC Feb 20 2026 Call Entry: $0.25 Exit: $0.48 ROI: 92% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OX50
OX50 Jan. 28 at 5:51 PM
$FULC Consensus: Twelve analysts give Fulcrum Therapeutics a consensus rating of "Moderate Buy" (1 strong buy, 7 buy, 1 hold, 3 sell) with an average 12‑month target of $19.11.
0 · Reply
Latest News on FULC
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Feb 17, 2026, 8:00 AM EST - 3 days ago

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2026, 4:30 PM EST - 14 days ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:46 PM EST - 5 weeks ago

Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 6 weeks ago

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 10, 2025, 7:48 AM EST - 2 months ago

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

Dec 8, 2025, 4:01 PM EST - 2 months ago

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results

Dec 8, 2025, 1:06 PM EST - 2 months ago

Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results

Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript

Dec 7, 2025, 11:03 AM EST - 2 months ago

Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Dec 6, 2025, 5:30 PM EST - 2 months ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

Dec 2, 2025, 8:30 AM EST - 2 months ago

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Nov 3, 2025, 4:45 PM EST - 3 months ago

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Fulcrum Therapeutics, Inc. (FULC) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 2:56 PM EDT - 4 months ago

Fulcrum Therapeutics, Inc. (FULC) Q3 2025 Earnings Call Transcript

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

Oct 29, 2025, 7:00 AM EDT - 4 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

Oct 22, 2025, 8:54 AM EDT - 4 months ago

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

Aug 26, 2025, 8:00 AM EDT - 6 months ago

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Jul 29, 2025, 6:48 AM EDT - 7 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jul 29, 2025, 6:45 AM EDT - 7 months ago

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jul 28, 2025, 4:01 PM EDT - 7 months ago

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

May 29, 2025, 4:10 PM EDT - 9 months ago

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 29, 2025, 8:30 AM EDT - 9 months ago

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Fulcrum Therapeutics to Participate in Upcoming May Conferences

May 8, 2025, 4:05 PM EDT - 10 months ago

Fulcrum Therapeutics to Participate in Upcoming May Conferences

Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript

May 1, 2025, 1:55 PM EDT - 10 months ago

Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

May 1, 2025, 7:00 AM EDT - 10 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

Apr 24, 2025, 8:00 AM EDT - 10 months ago

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Mar 4, 2025, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 10:58 PM EST - 1 year ago

Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Feb 18, 2025, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 6, 2025, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Nov 26, 2024, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:48 PM EST - 1 year ago

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Nov 6, 2024, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Oct 2, 2024, 6:30 PM EDT - 1 year ago

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation

Oct 1, 2024, 6:15 PM EDT - 1 year ago

Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Sep 30, 2024, 8:00 PM EDT - 1 year ago

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out

Sep 28, 2024, 8:00 PM EDT - 1 year ago

The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws

Sep 27, 2024, 6:30 PM EDT - 1 year ago

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws

elmono
elmono Feb. 20 at 7:35 PM
$FULC which retail retards are taking a few dimes profit? ….Tell me 😂😂😂
0 · Reply
HeraklesTrading
HeraklesTrading Feb. 20 at 9:10 AM
$FULC 20 mg, 12 weeks baby !! clear signs of dose response AND almost clear signs of time response !! That's why I'd expect fantastic full 12 weeks results on Tuesday ;) buckle up, above above $20 next week ;)
0 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Feb. 19 at 8:21 PM
$FULC new fda guideline means if fulc has same data at 12week as 6 week, they might try to file priority review, breakthrough, skip P3.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 2:59 PM
$FULC Current Stock Price: $11.31 Contracts to trade: $11.0 FULC Feb 20 2026 Call Entry: $0.52 Exit: $0.67 ROI: 29% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Feb. 18 at 5:50 PM
$FULC totally normal. Gsk bought 1.8m shares in fulc right? And all the top hedge funds entered. I'm waiting for the party or the funeral next Tuesday.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 11:11 PM
$FULC RSI: 51.44, MACD: -0.0898 Vol: 0.42, MA20: 10.50, MA50: 10.99 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OceanDeepValue
OceanDeepValue Feb. 4 at 3:45 PM
$FULC is a clinical-stage biotech (Fulcrum Therapeutics) developing therapies for genetically defined diseases; its pipeline is in mid-stage trials, representing a binary investment.
0 · Reply
elmono
elmono Feb. 2 at 8:48 PM
$FULC fuck fulc
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 29 at 1:10 AM
$FULC Current Stock Price: $10.49 Contracts to trade: $10 FULC Feb 20 2026 Call Entry: $0.25 Exit: $0.48 ROI: 92% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OX50
OX50 Jan. 28 at 5:51 PM
$FULC Consensus: Twelve analysts give Fulcrum Therapeutics a consensus rating of "Moderate Buy" (1 strong buy, 7 buy, 1 hold, 3 sell) with an average 12‑month target of $19.11.
0 · Reply
nycpupster
nycpupster Jan. 23 at 11:05 PM
$FULC another biotech primed
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 22 at 5:09 PM
$FULC
0 · Reply
Merlintrader
Merlintrader Jan. 21 at 10:47 PM
$FULC https://www.merlintrader.com/fulc-fulcrum-therapeutics-2/
1 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Jan. 14 at 7:08 PM
$FULC nothing new at jpm. But data is due this q1. Ceo sounded bullish as expected.
0 · Reply
momyurich
momyurich Jan. 12 at 5:13 PM
$FULC Today JP Morgan initiated PT $20 👍📈
0 · Reply
momyurich
momyurich Jan. 12 at 5:08 PM
$FULC Their new presentation https://www.sec.gov/Archives/edgar/data/1680581/000119312526009845/fulc-ex99_1.htm
0 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Jan. 12 at 2:59 PM
$FULC even jpm buy rating at jpm does nothing. Either tutes selling out because no faith in the 20mg dose or manipulation into a pending data or deal.
1 · Reply
notreload_ai
notreload_ai Jan. 12 at 12:41 PM
Goldman Sachs and JPMorgan highlight new clinical data that strengthen the outlook for $CRNX and $FULC , citing clearer paths to success and upside potential. https://notreload.xyz/goldman-jpmorgan-turn-bullish-on-crnx-and-fulc/
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 12:37 PM
$FULC 07:33 on Jan. 12 2026 JP Morgan Initiates Coverage On Fulcrum Therapeutics with Overweight Rating, Announces Price Target of $20 #tradeideas
0 · Reply
OX50
OX50 Jan. 11 at 11:32 PM
$FULC One day you are going to wake up to see FULC suddenly jumps over 100%. This is a great long term hold.
0 · Reply
elmono
elmono Jan. 7 at 4:30 PM
$FULC in the midfle of a shitstorm….with next read out soon 🤷‍♂️…..next BO?
0 · Reply
Biohacker
Biohacker Jan. 6 at 7:58 PM
$FULC if you like penny bios and actually want make to make money just short them on news spikes .Statistically you will win 90% of the time .There are AI programs that specialize in this strategy .
0 · Reply